1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Janssen Ad26.COV2.S: new trials by email Literature Review of Janssen Ad26.COV2.S trials Research Report on Janssen Ad26.COV2.S
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention Alveavax-v1.2, Janssen Ad26.COV2.S - Sars-CoV-2 Infection | Phase 1 | Completed | Alvea Holdings, LLC | 130 | 2022-06-27 | 2023-05-06 |
COVID-19 (1) · Severe Acute Respiratory Syndrome (1)
South Africa (1)